Biochemical markers subtyping major depressive disorder

Area of Science:

• Neuroscience
• Psychiatry
• Biochemistry

Background:

• The pathophysiology of major depressive disorder (MDD) is not fully understood, hindering the development of reliable clinical biomarkers.
• MDD's heterogeneity suggests distinct biological subgroups may exist, complicating diagnosis and treatment.
• Current clinical practice lacks objective biochemical markers for diagnosing and subtyping MDD.

Purpose of the Study:

• To review promising biological systems and markers for subtyping major depressive disorder (MDD).
• To explore the potential of the dopamine system, hypothalamic-pituitary-adrenal (HPA) axis, and chronic inflammatory markers in MDD subtyping.
• To integrate current understanding of these biological systems for a more refined view of MDD pathophysiology.

Main Methods:

• Review of existing scientific literature on dopamine system, HPA axis, and inflammatory markers in MDD.
• Analysis of evidence linking dopamine responsiveness to a subset of MDD.
• Examination of hormonal challenge tests (e.g., dexamethasone/corticotrophin-releasing hormone test) for HPA axis dysfunction in depressive disorders.
• Assessment of studies on neuroinflammation and tryptophan-kynurenine pathway alterations in MDD patients.

Main Results:

• Evidence suggests a dopamine agonist-responsive subtype of MDD.
• Depressive disorders exhibit a range of HPA axis activity, from hypercortisolism to hypocortisolism, detectable via hormonal tests.
• A subset of MDD patients displays characteristics of chronic inflammatory diseases, including neuroinflammation and altered tryptophan metabolism via the kynurenine pathway.

Conclusions:

• Subtyping MDD using biological markers like dopamine, HPA axis function, and inflammatory profiles is a promising avenue.
• Understanding the interplay between these systems is crucial for advancing MDD pathophysiology and personalized treatment strategies.
• Further research is needed to validate these markers and integrate them into clinical practice for improved MDD management.